{"id":63418,"date":"2026-04-17T20:44:35","date_gmt":"2026-04-17T12:44:35","guid":{"rendered":"https:\/\/flcube.com\/?p=63418"},"modified":"2026-04-17T20:44:36","modified_gmt":"2026-04-17T12:44:36","slug":"betta-pharmaceuticals-partners-with-eversana-for-us-commercialization-of-ensartinib-in-alk-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=63418","title":{"rendered":"Betta Pharmaceuticals Partners with Eversana for US Commercialization of Ensartinib in ALK+ NSCLC"},"content":{"rendered":"\n

Betta Pharmaceuticals Co., Ltd.<\/strong> (SHE: 300558<\/a>), a China-based oncology-focused biopharma company, has entered into a strategic licensing agreement<\/strong> with US-headquartered Eversana<\/strong>, a leading global provider of integrated commercial services to the life sciences industry. The deal grants Eversana exclusive commercialization rights<\/strong> in the United States for Ensacove (ensartinib)<\/strong>, an anaplastic lymphoma kinase (ALK) inhibitor<\/strong>.<\/p>\n\n\n\n

Deal & Asset Overview<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Licenser<\/strong><\/td>Betta Pharmaceuticals Co., Ltd. (SHE: 300558)<\/td><\/tr>
Licensee<\/strong><\/td>Eversana (USA)<\/td><\/tr>
Asset<\/strong><\/td>Ensacove (ensartinib)<\/td><\/tr>
Indication<\/strong><\/td>First-line treatment of ALK-positive locally advanced or metastatic non-small cell lung cancer (NSCLC)<\/td><\/tr>
Territory<\/strong><\/td>United States<\/td><\/tr>
Financial Terms<\/strong><\/td>Undisclosed<\/td><\/tr>
Development Origin<\/strong><\/td>Co-developed by Betta and its affiliate, Xcovery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regulatory & Market Timeline<\/h2>\n\n\n\n